Most Popular
-
1
Ador CEO denies allegations, accuses Hybe of mistreating NewJeans
-
2
10-man S. Korea lose to Indonesia to miss out on Paris Olympic football qualification
-
3
Hybe-Ador feud should have limited effect on Hybe's overall performance: analysts
-
4
Second Gimpo civil servant found dead, after apologizing for not finishing work
-
5
DP leader says he will meet Yoon without conditions
-
6
Seoul to promote luxurious side of the city
-
7
First-ever meeting of president, opposition chief set to finally happen
-
8
NewJeans' singles, Japanese debut to proceed as planned, despite Hybe-Ador feud
-
9
Experts raise concerns about Japan putting pressure on Naver over Line
-
10
Samsung mobile chief, Google device head meet in Seoul
[DISCLOSURE] Macrogen (038290), a genome sequencing firm, announced on Sept. 21 that it has gained a patent for extracting fusion protein that encodes RET fusion protein which can be used as a diagnostic marker of cancer.
The patent includes primer pair of base sequence to detect KIF5B fusion protein and composite to inhibit activation of relevant fusion protein of lung cancer.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
The patent includes primer pair of base sequence to detect KIF5B fusion protein and composite to inhibit activation of relevant fusion protein of lung cancer.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
